Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.
Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.
Legend reported results Tuesday on 12 lymphoma …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Trial phase launched at cell therapy center for cancer treatment - Türkiye News
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
It’s a crucial moment for the cell and gene therapy field. At the American Society of Gene & Cell Therapy’s annual meeting,…
VIDEO: CAR-T in the frontline setting, other promising areas of research in myeloma
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, highlights upcoming clinical trials in multiple…
